Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans by unknown
RESEARCH Open Access
Consumption of echium oil increases EPA
and DPA in blood fractions more efficiently
compared to linseed oil in humans
Katrin Kuhnt1*, Stefanie Weiß1, Michael Kiehntopf2 and Gerhard Jahreis1
Abstract
Background: A plant-based strategy to improve long-chain (LC) omega (n)-3 PUFA supply in humans involves
dietary supplementation with oils containing α-linolenic acid (ALA) alone or in combination with stearidonic acid
(SDA). The study aimed to compare the effects of echium oil (EO) and linseed oil (LO) on LC n-3 PUFA
accumulation in blood and on clinical markers.
Methods: In two double-blind, parallel-arm, randomized controlled studies, all volunteers started with 17 g/d run-in
oil (2 weeks). Thereafter, subjects received diets enriched in study 1 with EO (5 g ALA + 2 g SDA; n = 59) or in study
2 with LO (5 g ALA; n = 59) daily for 8 weeks. The smaller control groups received fish oil (FO; n = 19) or olive oil
(OO; n = 18). Participants were instructed to restrict their dietary n-3 PUFA intake throughout the studies (e.g., no fish).
To investigate the influence of age and BMI on the conversion of ALA and SDA as well as clinical markers, the subjects
recruited for EO and LO treatment were divided into three subgroups (two age groups 20–35 y; 49–69 y with
BMI 18–25 kg/m2 and one group with older, overweight subjects (age 49–69 y; BMI >25 kg/m2).
Results: In plasma, red blood cells (RBC), and peripheral blood mononuclear cells (PBMC), EPA and docosapentaenoic
acid (DPA) were ~25 % higher following EO compared to LO. Comparing all treatments, the effectiveness of increasing
EPA and DPA in plasma, RBC, and PBMC was on average 100:25:10:0 and 100:50:25:0 for FO:EO:LO:OO, respectively. EO
led to a lower arachidonic acid/EPA-ratio compared to LO in plasma, RBC, and PBMC. Following EO, final DHA
was not greater compared to LO. Higher BMI correlated negatively with increases in plasma EPA and DPA after EO
supplementation, but not after LO supplementation. Decreasing effect on plasma LDL-C and serum insulin was greater
with EO than with LO.
Conclusions: Daily intake of SDA-containing EO is a better supplement than LO for increasing EPA and DPA in blood.
However, neither EO nor LO maintained blood DHA status in the absence of fish/seafood consumption.
Trial registration: ClinicalTrials.gov Reg No. NCT01856179; ClinicalTrials.gov Reg No. NCT01317290.
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Background
A high concentration of long-chain (LC) n-3 PUFA in hu-
man tissue is associated with a lower risk of cardiovascular
disease (CVD) [1, 2]. Thus, there has been an increasing
interest in incorporating n-3 PUFA into the diet. In order
to meet dietary eicosapentaenoic acid (20:5n-3; EPA) and
docosahexaenoic acid (22:6n-3; DHA) recommendations,
the American Heart Association recommends consump-
tion of two servings of fish (particularly oily fish) per week
[3]. However, the provision of marine LC n-3 PUFA for
the (increasing) human population made difficult by prob-
lems such as the overfishing and pollution of the marine
environment. Further, not everyone eats fish and some
people suffer from fish protein allergy. Hence, there is a
need to find alternative sources of LC n-3 PUFA for both
human nutrition and aquaculture fish feed.
Linseed oil (Linum usitatissimum L.), also known as
flaxseed oil, which naturally contains up to 60 % of the
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plant-based α-linolenic acid (18:3n-3, ALA), is the essen-
tial precursor of LC n-3 PUFA metabolites [4]. Supple-
mentation with linseed oil has previously been shown to
increase n-3 PUFA stores in humans. However, conver-
sion of ALA to LC n-3 PUFA is limited and insufficient
to achieve adequate tissue levels of EPA. DHA synthesis,
in particular, is extremely limited [5–8].
Over the past few years, several novel dietary sources
of LC n-3 PUFA for human consumption have been
considered [9, 10]. High potential to improve LC n-3
PUFA supply has stearidonic acid (18:4n-3, SDA), another
plant-based n-3 PUFA and an intermediate of ALA. SDA
is present in high concentrations in some plant families,
such as Primulaceae and especially Boraginaceae [11].
Seed oils from echium species (Boraginaceae) are unique
due to their high concentrations of SDA and ALA to-
gether with γ-linolenic acid (18:3n-6, GLA) [11]. Oil from
Echium plantagineum is an approved novel food available
as a food ingredient. In humans, the ability of SDA to in-
crease EPA in blood is higher than that of ALA, presum-
ably because it bypasses the rate-limiting Δ6-desaturase
step [12]. Transgenic SDA-containing soybean (16–28 %
SDA), canola, and linseed oils have been developed
[13, 14] and recently studied [14–17]. However, gen-
etically modified foods are to date not well accepted
by consumers in Europe [9]. Therefore, naturally
occurring echium oil and linseed oil were chosen for
the present project.
In general, SDA-containing oils possess potent anti-
lipidemic and hepatoprotective effects. Echium oil has
been shown to lower serum triglycerides [18–20]. There-
fore, it is likely that echium oil may play a role in prevent-
ing progression of CVD and type 2 diabetes mellitus.
The primary aim of the entire project including the
two present studies was to compare the increase of LC
n-3 PUFA in plasma, RBC, and PBMC after consump-
tion of 5 g ALA + 2 g SDA from natural echium oil
(study 1) compared to only ALA (5 g) from linseed oil
(study 2) under the same study conditions. The second-
ary aim was to investigate the influence of sex, increased
age and higher BMI on conversion of ALA and SDA as
well as on clinical blood markers. As controls for fatty
acid metabolism, n-3 PUFA-poor olive oil (negative control)
and EPA-fish oil (positive control) were supplemented
throughout the entire project.
Methods
Ethics statement
The entire project including two randomized, double-
blind, parallel-arm controlled studies were carried out in
accordance with the Declaration of Helsinki of the World
Medical Association, approved by the Ethics Committee of
the Friedrich Schiller University Jena (No. 2270-04/08) and
registered in the Clinical Trials Registry (ClinicalTrials.gov
ID: NCT01856179 and NCT01317290). Written informed
consent was obtained from all participants.
Subjects
The recruitment for echium oil (EO; study 1, n = 60) and
linseed oil (LO; study 2, n = 60) intervention was carried
out according to age and BMI in three subgroups (sub-
group I: BMI of 18–25 kg/m2, 20–35 years; subgroup II:
BMI of 18–25 kg/m2, 49–69 years, n = 20; and subgroup
III: overweight subjects, BMI > 25 kg/m2) (Fig. 1). Only
normal-weight subjects in two age subgroups (20–35 y
and 49–69 y) were recruited for the smaller control
groups: fish oil (FO, positive control, study 1, n = 20)
and olive oil (OO, negative control, study 2, n = 20).
Gender was balanced in all groups. Recruitment of par-
ticipants for the fish oil and echium oil interventions in
study 1 (2011) has been described previously [20].
The subjects from study 1 were asked to participate in
the subsequent study 2 (2012) to increase comparability.
Former EO subjects were allocated to supplementation
with LO, while former FO subjects were allocated to OO
supplementation. In total, 80 % of the older subjects and
50 % of the younger subjects participated again in study 2.
Exclusion criteria for both studies included: vegetarianism,
veganism, daily alcohol abuse, pregnancy, lactation, chronic
diseases, use of blood pressure-, cholesterol-, or TG-
lowering medications or dietary supplements.
Experimental design and diets
The two studies were performed according to same condi-
tions (design, diets and analytical methods) as previously
published [20, 21]. The same investigator and technical
staff conducted both studies. Both studies started with
a 2-weeks run-in period, in which all enrolled subjects
(each n = 80) consumed 17 g/d of the same run-in oil.
After that, subjects received the oil treatment for 8 weeks.
In study 1, two thirds were randomly allocated to receive
EO (n = 20 per subgroup) and one third was randomly
allocated to FO (n = 10 per subgroup). In study 2, the
newly recruited subjects were also randomly allocated
to receive LO (n = 20 per subgroups I& II) and to OO
(n = 10 per subgroups I&II).
Thus, in study 1 comprised EO (n = 60) and FO (n = 20)
and in study 2 comprised LO (n = 60) and OO (n = 20)
(Fig. 1). In order to reduce dietary intake of additional
n-3 PUFA and linoleic acid (18:2n-6; LA) during the
10-week study, the participants were encouraged to
avoid consuming the following foods: fish, fish oils, sea-
food, n-3 PUFA-rich foods, linseed and rapeseed oil, as
well as margarine and common LA-rich sunflower oil.
To reduce variation in dietary FA intake before blood
sampling at day 0 and day 56, all volunteers received
a defined diet for three successive days as described
previously [20, 22].
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Supplemented oils
The run-in oil in both studies contained a mixture of
fats and oils [20, 21] to represent the FA distribution of
the Western diet. All four treatment groups received ap-
proximately 17 g/d of the respective study oil (Table 1).
To balance the fat intake, also 17 g of run-in oil were
supplemented in the first 2 weeks (run-in period) (Fig. 1;
Table 1). The EO subjects received EO (seed oil of E.
plantagineum, INCROMEGA V3, Croda; two table-
spoons) containing an average of 5 g ALA, 2 g SDA and
2 g GLA (Table 1). The LO subjects were supplemented
with 5 g ALA from linseed oil (Erfurter Ölmühle) [21].
Fig. 1 Flow diagram of subjects through study 1 and study 2. Subjects from study 1 who agreed to a repeat participation were implemented in
study 2; former EO subjects were supplemented with LO in study 2; former FO subjects were supplemented with OO in study 2. EO, echium oil;
FO, fish oil; LO, linseed oil mixture; OO, olive oil. Subgroup I, age 20–35 years and BMI 18–25 kg/m2; subgroup II, age 49–69 years and BMI
18–25 kg/m2; subgroup III, age 49–69 years and BMI >25 kg/m2
Table 1 FA profile and daily FA dose with run-in oil and with treatment oilsa
Run-in period (2 weeks) Intervention period (8 weeks)
Treatment Run-in oil (n = 155) Echium oil (study 1)
(n = 59)
Linseed oil mixture
(study 2) (n = 59)
Control groups
Fish oilb (study 1)
(n = 19)
Olive oil (study 2)
(n = 18)
% g/d % g/d % g/d % g/d % g/d
Oil dose 17 17 17 17 17
FA groups and individual FA
∑SFA 44 7.5 11 1.8 9.0 1.4 12 2.1 14 2.1
∑MUFA (mainly 18:1n-9) 39 6.7 18 3.0 38 5.9 66 12 80 12
∑PUFA 16 2.8 70 12 53 8.1 22 3.3 6.0 0.9
18:2n-6, LA 16 2.8 17 2.9 22 3.3 5.7 0.9 5.5 0.8
18:3n-6, GLA − − 11 1.8 − − 0.1 − − −
18:3n-3, ALA 0.2 − 30 5.0 31 4.9 0.6 0.1 0.5 0.1
18:4n-3, SDA − − 12 2.0 − − 1.2 0.2 − −
20:5n-3, EPA − − − − − − 11 1.9 − −
22:5n-3, DPA − − − − − − 0.2 − − −
22:6n-3, DHA − − − − − − 1.4 0.2 − −
n-6/n-3 80/1 0.7/1 0.7/1 0.4/1 11/1
aData are means of men and women. - indicates < 0.1 g/100 g or < 0.1 g/d. bFish oil (EPA:DHA, 9:1) blended with olive oil
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The linseed oil was blended with common sunflower oil
and a plant oil mixture (K-Classic) to obtain similar
ALA dosage, n-6/n-3 ratio and LA content as in EO
[16], (Table 1). The control groups received EPA-rich
FO as positive control (1.9 g/d EPA; CRODA EPA-TG-
500) or highly refined OO as n-3 PUFA-poor negative
control (Gustav Heess). Female subjects received a
slightly smaller quantity of study oil than male partici-
pants (15.5 g/d vs. 18.5 g/d) [20]; to provide comparable
amounts of ALA (~2 % of total energy intake) for both
genders. The handling of study oils and blinding was
similar as previously stated [20, 21].
Blood sampling
Blood was collected at the Institute of Nutrition in Jena
following the 2-weeks run-in period (day 0), and after 7
and 56 days of oil supplementation. Blood sampling
methods and for preparation of blood fractions such as
plasma, RBC, and peripheral blood mononuclear cells
(PBMC) were described previously [20–22].
Biochemical markers
Total cholesterol (TC), HDL-C, LDL-C, and TG (enzymatic
colorimetric), oxLDL (ELISA), high sensitivity C-reactive
protein and lipoprotein (a) (immunoturbidimetric), insulin
(immunochemiluminometric) were analyzed according to
the methods of the Institute of Clinical Chemistry and
Laboratory Medicine at Jena University Hospital [20].
Anthropometric parameters
Waist circumference, blood pressure, body composition
(50 kHz-frequency impedance analyzer; Data Input) and
body weight were recorded after the run-in period (day 0)
and intervention period (day 56).
Fatty acid analysis
Preparation of plasma, RBC, and PBMC fractions, and
lipid extraction with chloroform/methanol/water (2:1:1,
v:v:v) were performed as described by Kuhnt et al.
[20–22]. In brief, FA were methylated with methanolic
boron trifluoride into fatty acid methyl esters (FAME).
Following purification by thin layer chromatography,
FAME were analyzed by gas chromatography (GC)
with flame ionization detector (60 m column length;
DB225MS, Agilent Technologies). In all analyzed blood
fractions, the same 47 FA were integrated (C10–C24).
Individual FAME were expressed as a percentage of
total identified FAME peak areas [% of total (Σ)
FAME]. Samples were blinded during FA analysis.
The reference standards used as FAME included: No.
463, 674 (Nu-Check Prep), BR2, BR4, ME93 (Larodan),
Supelco®37 Component FAME Mix (Supelco) and PUFA
No.3 (Matreya LLC). LabSolutions was used for GC peak
integration (Shimadzu).
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware 19.0. (IBM Corporation). The results are stated as
means ± SD unless otherwise noted. The treatment ef-
fects on FA and biochemical markers were analyzed
using the linear mixed model. Each variable was evalu-
ated using analysis of covariance (ANCOVA) with sex,
age, BMI, and the respective baseline value as covariates.
Oil treatment as a factor for main effects and sex, age,
and BMI as factors for interaction, were included in
order to control type I. The differences between sub-
group characteristics within and between treatments at
baseline (day 0) were analyzed using subgroups as fixed
factors without covariates (ANOVA). To examine the
effect of time (day 0 to day 56) for total subjects of
each treatment, repeated measures ANCOVA was
used. In general, the P values of the pairwise compari-
sons were stated and were adjusted by using the step-
down Bonferroni method. Pearson correlation analyses
were conducted to test associations. Statistical significance
was set at P ≤ 0.05 for all analyses.
Results
Characteristics of subjects
In the subgroups II and III with higher age and BMI, an-
thropometric measures and clinical markers were gener-
ally greater (except HDL-C) (Table 2). Weight gain, waist
circumference, BMI, and portion of body fat did not differ
between EO and LO treatments (data not shown).
Fatty acid composition in blood fractions
Run-in period
Following the run-in period, of those who completed the
study (n = 154), women had a lower plasma docosapentae-
noic acid (22:5n-3, DPA) but a higher plasma DHA than
men (P ≤ 0.001). Age was positively correlated with plasma
EPA, DPA, and DHA (r = 0.538, 0.388, 0.279; P ≤ 0.001, re-
spectively). BMI was also positively correlated with plasma
EPA and DPA (r = 0.262, P ≤ 0.001; r = 0.172, P = 0.033)
but not with plasma DHA (r = 0.12, P = 0.13).
Intervention period
Following 8 weeks of EO and LO supplementation, signifi-
cant increases in ALA, SDA and the LC n-3 PUFA metab-
olites eicosatetraenoic acid (20:4n-3; ETA) EPA, and DPA
were found in plasma, RBC, and PBMC (P < 0.01; Table 3).
However, in all blood fractions the increase in ETA, EPA,
and DPA were approximately 40–60 % higher with EO
than with LO. In general, the greatest increase of ETA,
EPA and DPA were found in plasma, followed by PBMC
and RBC (Table 3). Final EPA and DPA in plasma, RBC,
and PBMC were consistently higher (15–35 %) compared
to LO, respectively (P < 0.05; Table 4). DHA did not accu-
mulate with EO or LO and instead decreased in plasma,
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RBC, and PBMC; however, the decrease in plasma was
lower with EO vs. LO (P = 0.008) (Table 3). The final
plasma DHA was higher with EO compared to LO, but
lower in PBMC (P < 0.01; Table 4).
Considering all treatments, increases in plasma, RBC,
and PBMC of EPA were highest with FO (~520 %),
followed by EO (~117 %), LO (~48 %), and OO (~0 %,
P < 0.001; Table 3). The increase in plasma, RBC, and
PBMC DPA was also significantly the highest with FO
(94 %), but with a lower distance to EO (47 %), LO
(23 %), and OO (0 %; Table 3). Overall, final EPA and
DPA in plasma, RBC and PBMC were in similar order:
FO > EO > LO >OO (P ≤ 0.001; not for DPA in RBC;
Table 4). In plasma and PBMC, DHA was highest
following FO, but was not different in RBC compared to
EO or LO (Table 4).
With respect to n-6 PUFA, EO supplementation in-
creased GLA in plasma, RBC, and PBMC and was great-
est compared to the remaining oil treatments (Table 3).
In addition, DGLA and AA (the LC metabolites of GLA)
also increased in all blood fractions, except for AA in
PBMC (Table 4). Therefore, in all blood fractions, final
GLA and DGLA were the highest with EO (P < 0.001;
data not shown). The ratio of AA/EPA in plasma, RBC,
and PBMC was lowest with FO compared to EO vs. LO
vs. OO (P < 0.001; Fig. 2). The final AA/EPA ratio in
plasma and PBMC was lower (P < 0.001) with EO vs.
LO, but in RBC only as a trend (P = 0.09; Fig. 2).
In subjects consuming EO, BMI was negatively cor-
related with the relative increase in plasma EPA and
DPA. In subjects consuming LO, there were no corre-
lations to BMI in line with the non-interaction with
BMI (data not shown).
Effects on clinical markers
Correlations between age, BMI, anthropometrical and
biochemical markers reflect differences in baseline char-
acteristics between age and BMI subgroups (Table 2).
Change in HDL-C was clearly contrasting between EO
and LO (Table 5), HDL-C decreased with EO, but in-
creased with LO. Therefore, final HDL-C was lower with
EO vs. LO (Table 5). The LDL-C decrease was greater
with EO vs. LO. Finally, HDL-C/LDL-C ratio was lower
with LO vs. EO. Plasma concentration of TC and TG de-
creased with EO, but final values did not differ between
EO and LO (Table 5).
In the control groups, FO showed the strongest TG
reduction (−17 %), while TG increased with OO (+10 %;
data not shown). The serum concentration of oxLDL
decreased with both EO and LO; however, the significant
difference between final oxLDL in the EO and LO groups
(Table 5) was due to the significantly lower baseline values
Table 2 Characteristics of the study subgroups following the run-in period (day 0), prior to receiving echium oil or linseed oil mixture1
Study 1 Echium oil Study 2 Linseed oil mixture
Subgroups EOI (n = 20) EOII (n = 20) EOIII (n = 19) LOI (n = 20) LOII (n = 20) LOIII (n = 19)
Sex, f/m 10/10 11/9 9/10 10/10 10/10 10/9
BMI group (kg/m2) 18–25 18–25 >25 18–25 18–25 >25
Age group (years) 20–35 49–69 49–69 20–35 49–69 49–69
Repeated participation (%) 40 90 80
Age (years) 28.1 ± 2.86b 58.8 ± 5.73a 61.2 ± 6.26a 25.0 ± 3.43b 59.0 ± 5.56a 61.1 ± 7.28a
Body mass index (kg/m2) 22.0 ± 2.34b 23.5 ± 2.40b 30.1 ± 3.30a 22.3 ± 2.24b 23.2 ± 2.27b 29.5 ± 3.26a
Waist circumference (cm) 80.3 ± 9.10c 87.2 ± 9.17b 104 ± 6.75a‡ 80.7 ± 4.95c 86.3 ± 7.71b 99.4 ± 7.19a
Systolic BP (mm Hg) 125 ± 10.4b* 135 ± 19.9ab 141 ± 15.6a‡ 133 ± 17.3b 148 ± 20.2b 154 ± 24.0a
Diastolic BP (mm Hg) 82.2 ± 8.9b 90.1 ± 12.3a 91.2 ± 7.90a 82.4 ± 6.68a 89.5 ± 10.7a 85.3 ± 19.8a
Total cholesterol (mmol/L) 4.52 ± 0.68b 5.82 ± 1.24a 6.30 ± 1.02a 4.43 ± 0.80b 5.58 ± 1.32a 5.84 ± 1.09a
HDL-C (mmol/L) 1.43 ± 0.30a 1.58 ± 0.47a 1.33 ± 0.32a 1.39 ± 0.27a 1.44 ± 0.38a 1.30 ± 0.33a
LDL-C (mmol/L) 2.54 ± 0.61b 3.54 ± 0.89a 3.95 ± 0.90a 2.48 ± 0.75b 3.36 ± 0.98a 3.70 ± 0.97a
LDL-C/HDL-C 1.87 ± 0.67b 2.37 ± 0.66b 3.08 ± 0.75a 1.86 ± 0.70b 2.42 ± 0.70a 2.90 ± 0.83a
Triglycerides (mmol/L) 0.89 ± 0.36b 1.14 ± 0.42b 1.82 ± 0.88a‡ 0.97 ± 0.39a 1.31 ± 0.94a 1.39 ± 0.51a
Oxidized LDL (mmol/L) 67.7 ± 12.7c* 80.3 ± 11.4b* 92.9 ± 13.2a* 49.9 ± 18.0b 60.8 ± 15.2a 66.6 ± 14.2a
High sensitivity CRP (mg/L) 0.68 ± 0.62a 1.35 ± 2.03a 2.12 ± 2.41a 1.32 ± 1.60a 1.25 ± 1.50a 1.64 ± 1.43a
Insulin (mU/L) 6.03 ± 2.35b 9.75 ± 5.90a 11.6 ± 4.77a 6.22 ± 2.57b 7.96 ± 4.92a 10.8 ± 6.78a
1Values are means ± SD. C cholesterol. EO echium oil, LO linseed oil mixture; I, age 20–35 years and BMI 18–25 kg/m2; II, age 49–69 years and BMI 18–25 kg/m2; III,
age 49–69 years and BMI >25 kg/m2. P values were analyzed using the generalized linear mixed model ANOVA
abcWithin one oil treatment, means within a row with different superscript letters are significantly different between subgroups (P ≤ 0.05)
*Mean values are significantly different between the respective EO and LO subgroups (I, II, III) (*P ≤ 0.05, ‡P 0.05 < 0.10)
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Table 3 Percent change of FA in plasma, RBC, and PBMC in echium oil vs. linseed oil groups and in control groups after 8-weeks
treatment1
Change of FA, % Study 1 Echium
oil (n = 59)
Study 2 Linseed oil
mixture (n = 59)
Treatment effect
EO vs. LO P2
Control groups
Fish oil (n = 19) Olive oil (n = 18)
Plasma
n-3 PUFA ALA 230 ± 13b† 314 ± 20a† 0.001 −8 ± 4c 14 ± 5c†
SDA 789 ± 69a† 159 ± 13b† <0.001 59 ± 19b† 22 ± 14b
ETA 406 ± 32a† 124 ± 10b† <0.001 53 ± 12b† 27 ± 10b†
EPA 168 ± 8b† 67 ± 6c† <0.001 646 ± 75a† 4 ± 6d
DPA 68 ± 4b† 31 ± 3c† <0.001 113 ± 13a† −1 ± 2d
DHA −3 ± 3b −11 ± 2b† 0.008 39 ± 8a† −5 ± 3b
n-6 PUFA LA −9 ± 1b† 3 ± 1a† <0.001 −13 ± 2b† −8 ± 1b†
GLA 276 ± 23a† −11 ± 3b† <0.001 −16 ± 4b† 7 ± 6b
DGLA 67 ± 5a† −10 ± 2bc† <0.001 −26 ± 4c† 6 ± 3b
AA 14 ± 2a† −1 ± 2b <0.001 3 ± 3ab 0 ± 3b
22:5n-6 −20 ± 3b† −9 ± 3b† 0.006 −38 ± 7b† 12 ± 5a
RBC
n-3 PUFA ALA 156 ± 32b† 201 ± 9a† <0.001 −12 ± 5c 8 ± 3c†
SDA 405 ± 54a† 135 ± 22b† <0.001 6 ± 13c 49 ± 35b
ETA 243 ± 22a† 106 ± 7b† <0.001 24 ± 6c 9 ± 4c
EPA 85 ± 12b† 32 ± 4c† <0.001 351 ± 35a† −10 ± 3d†
DPA 32 ± 8b† 12 ± 2c† <0.001 75 ± 16a† −4 ± 2d
DHA −4 ± 2b† −10 ± 2b† 0.15 10 ± 9a −9 ± 2b†
n-6 PUFA LA 11 ± 3a 1 ± 1b <0.001 −11 ± 4b −4 ± 1b†
GLA 144 ± 16a† 0 ± 4b <0.001 1 ± 2b 7 ± 6b
DGLA 48 ± 9a† −5 ± 1b† <0.001 −15 ± 3b 3 ± 1b
AA 17 ± 3a† −1 ± 1b <0.001 2 ± 4b 0 ± 1b
22:5n-6 −2 ± 4a −4 ± 1a† 0.43 −29 ± 5b† 6 ± 2a
PBMC
n-3 PUFA ALA 147 ± 20b† 368 ± 28a† <0.001 70 ± 43bc 13 ± 8c
SDA 424 ± 78a† 103 ± 34b <0.001 −2 ± 24b 47 ± 45b
ETA 388 ± 35a† 81 ± 5b† <0.001 38 ± 6b† 27 ± 19b
EPA 97 ± 9b† 45 ± 5c† 0.005 564 ± 57a† −1 ± 4d
DPA 42 ± 5b† 27 ± 2c† 0.006 94 ± 8a† 3 ± 2c
DHA −20 ± 3b† −15 ± 1b† 0.12 2 ± 5a −4 ± 2ab
n-6 PUFA LA 8 ± 2a 5 ± 1a 0.42 6 ± 3a −7 ± 2b†
GLA 128 ± 14a† −1 ± 4b <0.001 12 ± 15b 7 ± 4b
DGLA 47 ± 17a† −1 ± 1b† <0.001 −15 ± 3b† 6 ± 2b
AA −2 ± 3a −2 ± 1a† 0.92 −10 ± 2b† 2 ± 1a
22:5n-6 −17 ± 6a† −8 ± 2a† 0.17 −48 ± 3b† 8 ± 4a
1Values are means ± SEM; adjusted means not shown. Change is from day 0 to day 56. EO echium oil, ETA 20:4n-3, eicosatetraenoic acid, LO linseed oil mixture,
RBC red blood cells, PBMC peripheral blood mononuclear cells. P values were analyzed using the generalized linear mixed model ANCOVA with sex, age, BMI,
baseline value as covariates
2P values for the treatment effect including only EO and LO groups
abcMeans with different superscript letters are significantly different between all treatments (P ≤ 0.05)
†Within one oil treatment, means are significantly different between day 0 and day 56 (repeated measures; P ≤ 0.05)
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Table 4 Final EPA, DPA, and DHA in plasma, RBC, and PBMC in echium oil vs. linseed oil groups and in control groups after 8-weeks
treatment1
% of total FAME Study 1 Echium
oil (n = 59)
Study 2 Linseed
oil mixture (n = 59)
Treatment effect
EO vs. LO P2
Control groups
Fish oil (n = 19) Olive oil (n = 18)
Plasma
EPA 1.63 ± 0.51b 1.07 ± 0.36c <0.001 3.91 ± 0.99a 0.55 ± 0.20d
DPA 0.72 ± 0.14b 0.54 ± 0.11c <0.001 0.84 ± 0.23a 0.43 ± 0.11d
DHA 1.49 ± 0.42bd 1.39 ± 0.34c 0.009 1.93 ± 0.55a 1.29 ± 0.39cd
RBC
EPA 1.51 ± 0.33b 1.11 ± 0.31c 0.001 2.05 ± 0.28a 0.67 ± 0.23d
DPA 2.68 ± 0.38ab 2.44 ± 0.36ab 0.049 2.94 ± 0.37a 2.07 ± 0.33c
DHA 3.80 ± 0.83ab 3.62 ± 0.74ab 0.35 4.15 ± 0.73a 3.39 ± 0.89b
PBMC
EPA 0.69 ± 0.21b 0.54 ± 0.14c <0.001 1.91 ± 0.45a 0.30 ± 0.07d
DPA 2.37 ± 0.55b 2.11 ± 0.37c <0.001 3.28 ± 0.38a 1.68 ± 0.23d
DHA 1.38 ± 0.39d 1.53 ± 0.34b 0.003 1.71 ± 0.28ac 1.51 ± 0.33bc
1Values are means ± SD; adjusted means are not shown. EO, echium oil, LO linseed oil mixture, PBMC peripheral blood mononuclear cells, RBC red blood cells.
P values were analyzed using the generalized linear mixed model ANCOVA with sex, age, BMI, baseline value as covariates
2P values for the treatment effect including only EO and LO groups






























































Fig. 2 Final AA/EPA ratio in plasma, RBC, and PBMC in subjects following 8 weeks of fish oil, echium oil, linseed oil mixture, or olive oil.
Values are means ± SEM. P values were analyzed using the generalized linear mixed model ANCOVA with sex, age, BMI, and baseline
value as covariates. abcWithin one blood fraction, means with different superscript letters are significantly different between treatment
groups (P ≤ 0.05). ***Means are significantly different between EO and LO treatment (P < 0.001; ‡P 0.05 < 0.10). AA, arachidonic acid; EO,
echium oil; FO, fish oil; LO, linseed oil; OO, olive oil
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in the LO group (Table 2). The insulin concentration in
serum decreased most with EO vs. LO (P < 0.001), while
OO remained unchanged (Table 5).
Discussion
Natural linseed oil contains a high portion of ALA
(60–70 %) but little to no SDA [23]. In contrast, due
to the high activity of Δ6-desaturase in Echium spe-
cies, there are high levels of SDA (10–15 %) and
GLA (8–12 %), the respective conversion products of
ALA and LA [10, 11]. In the present study, the major
aim was to investigate the effectiveness of SDA in EO
compared to SDA-free LO for increasing endogenous
LC n-3 PUFA stores in blood fractions under otherwise
equal conditions (e.g. amounts of ALA and LA, n-6/n-3
ratio). Therefore, it was necessary to blend the LO with
further plant oils. In addition, the habitual diet of partici-
pants contained no fish and seafood, which meant that
there was minimal intake of dietary EPA and DHA.
Increase in EPA and DPA
Eight weeks of EO supplementation led to a two- to
three-fold EPA and DPA increase in plasma and cellular
blood fractions compared to that achieved with LO. In
one of the first clinical studies investigating SDA metab-
olism [12], similar quantities of SDA ethyl esters were
compared with ALA (0.75 g and 1.5 g). The effectiveness
of SDA in increasing EPA in plasma and RBC was about
four-fold that of ALA [12]. In the present study, similar
results were achieved using the natural complex oils
(Tables 3 and 4). As the EO and LO supplements provided
similar amounts of ALA (~5 g), it is likely that the add-
itional 2 g of SDA provided by the EO was responsible for
the additional increase in EPA and DPA.
The relative effectiveness of the four tested oils in in-
creasing EPA and DPA in plasma, RBC, and PBMC was
100:25:10:0 and 100:50:25:0 for FO:EO:LO:OO, respect-
ively. Similar results were obtained for the EPA increase
in blood when purified ethyl esters of EPA, SDA, and
ALA were administered to healthy male and postmeno-
pausal female subjects (100:30:7) [12]. In contrast, in
muscle tissue in lambs supplemented with EO or LO,
only slight differences in LC n-3 PUFA were found [24].
As shown in Table 3, with respect to each oil treatment,
the different intensities of increase in FA clearly represents
the known metabolic pathway of n-3 and n-6 PUFA, as
previously reviewed [25]. In general, the increases in EPA
and DPA in RBC, considered as middle-to-long-term
markers for FA intake and metabolism [26], confirmed
that an 8-weeks EO or LO supplementation adequately
achieved significant accumulation.
No increase in DHA
Despite higher EPA and DPA in blood following EO
supplementation, no consistently higher DHA could be
observed compared to LO. In accordance with previous
studies of EO, SDA ethyl esters, and SDA-enriched soy-
bean oil, no increase in plasma, RBC, or PBMC DHA was
found following 8 weeks of EO supplementation in this
population [12, 15–18]. Previous clinical trials of ALA
supplementation from LO (~5 g/d) [27–29] found in-
creases in EPA (~50 %) with no change in DHA, similar
Table 5 Clinical markers in echium oil and linseed oil groups before and after 8-weeks treatment1
Study 1 Echium oil (n = 59) Study 2 Linseed oil mixture (n = 59) Treatment effect EO vs. LO P2
Total cholesterol (mmol/L) Day 0 5.53 ± 1.25 5.27 ± 1.24
Day 56 5.22 ± 1.17 *** 5.08 ± 1.20 0.59
HDL-C (mmol/L) Day 0 1.45 ± 0.38 1.38 ± 0.33
Day 56 1.37 ± 0.42 *** 1.58 ± 0.37 *** <0.001
LDL-C (mmol/L) Day 0 3.33 ± 0.99 3.16 ± 1.03
Day 56 3.03 ± 0.87 *** 3.05 ± 0.99 0.056
LDL-C/HDL-C Day 0 2.43 ± 0.84 2.38 ± 0.84
Day 56 2.36 ± 0.88 2.00 ± 0.70 *** <0.001
Triglycerides (mmol/L) Day 0 1.28 ± 0.70 1.22 ± 0.68
Day 56 1.13 ± 0.59 *** 1.12 ± 0.62 0.66
Oxidized LDL (mmol/L) Day 0 80.1 ± 16.0 58.9 ± 17.1
Day 56 75.8 ± 14.9 *** 54.0 ± 17.7 * <0.001
Insulin (mU/L) Day 0 9.07 ± 5.07 8.26 ± 5.26
Day 56 6.25 ± 4.54 *** 7.38 ± 3.69 * 0.011
1Values are means ± SD; adjusted means are not shown. C cholesterol, EO echium oil, LO linseed oil mixture. P values were analyzed using the generalized linear
mixed model ANCOVA with sex, age, BMI, baseline value as covariates
2P values for the treatment effect including only EO and LO groups
*Within one oil treatment, means are significantly different between day 0 and day 56 (repeated measures; ***P ≤ 0.001; *P ≤ 0.05)
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to the effects achieved in our study. It is possible that con-
version of DPA into DHA, which requires elongation, Δ6-
desaturation, and a final chain shortening by peroxisomal
β-oxidation, is limited by competition with dietary ALA
[30]. We hypothesized that EO could compensate a DHA
decline better than LO [20]. Surprisingly, the decrease in
DHA was not significantly greater in the LO or OO
groups compared to EO.
Influencing factors on ALA and SDA conversion
The metabolism of ALA and also of SDA may be influ-
enced by dietary factors, including amounts of ALA, LA,
EPA, DHA, and the n-6/n-3-ratio [20, 28, 31–34]. Redu-
cing the n-6/n-3 ratio in the diet may reduce the risk for
CVD, but increasing the absolute amount of LC n-3
PUFA may be more effective [35]. In the present study,
the EO and LO supplements provided similar n-6/n-3
and LA/ALA ratios, as well as absolute LA and ALA
amounts. However, the EO did provide additional n-6
GLA, which may have led to greater competition for Δ5-
desaturase and could decrease the efficacy of SDA con-
version. Nonetheless, it is likely that the additional GLA
was converted into DGLA, which has been also shown
with Ahiflower oil™, an SDA- and GLA-containing plant
oil from the Boraginaceae [36]. DGLA is metabolized to
series-1 prostaglandins and thromboxanes that have po-
tent anti-inflammatory and vasodilatory effects [25]. This
may account, in part, for some of the beneficial effects
of EO. AA, the direct product of DGLA, was only
slightly increased. Furthermore, due to enhanced EPA
accumulation, the AA/EPA ratio was lower in all blood
fractions with EO compared with LO. A reduction in the
AA/EPA ratio may have clinical relevance because AA-
derived eicosanoids tend to be more pro-inflammatory
and pro-aggregatory than eicosanoids derived from EPA
[35]. It has been proposed that a 75 % reduction in
plasma AA/EPA may impart clinically meaningful bene-
fits [34]. In the present study, EO and LO supplementa-
tion resulted in 60–70 % and 40–50 % lower plasma and
cellular AA/EPA ratio, respectively, compared to OO.
n-3 PUFA status is influenced by gender [37, 38], age
[29, 39], and BMI [39]. In the current study populations,
these factors appeared to influence baseline status, but
have less effect on net increases of EPA and DPA during
EO or LO consumption. In exception, during EO sup-
plementation higher BMI was associated with lower
increases of plasma EPA and DPA [20]. It may be
possible that the expression and/or activity of enzymes
necessary for SDA metabolism, such as elongases and
Δ5-desaturase, are dependent on BMI. In support of
this, a recent study comparing the effects of FO, SDA
oil, and LO in obese and lean Zucker rats, genotype
was a significant predictor for tissue FA composition
following treatments [40].
Clinical implications of EO supplementation
With respect to blood lipids/lipoproteins, EO supple-
mentation resulted in more beneficial changes than LO,
with the exception of HDL-C. In the majority of previ-
ous ALA-intervention studies (3–10 g/d; 6–12 weeks)
[27–29, 41–44], no significant changes in plasma choles-
terol fractions and TG were observed, despite increased
plasma EPA. The known lowering of TG with FO [9]
was confirmed with the present study (FO group). EO
supplementation reduced TG independently of sex, age,
and BMI [20]; however, these effects were not signifi-
cantly greater than those achieved by LO supplementa-
tion. In rats, the TG and TC lowering effects of EO or
SDA oil [19, 40] were explained by decreasing hepatic
TG and TC and by downregulation of hepatic genes in-
volved in FA and TG biosynthesis [19]. The cholesterol-
lowering effect of EO could also be due to naturally oc-
curring phytosterols (analyzed in E. wildpretii [45]), as is
assumed for LO [29]. As a decrease in LDL-C and an in-
crease in HDL-C is thought to reduce CVD risk, it is
difficult to infer the clinical ramifications of the decrease
in both LDL-C and HDL-C following EO supplementa-
tion. In contrast, LO supplementation resulted in an
HDL-C increase. However, no other clinical studies of
LO have found an increase in HDL-C [5, 29, 41, 42], ex-
cept in non-smoking men [43]. Effects on oxLDL with
supplementation of n-3 PUFA plant oils are rare. Com-
pared to wheat, LO showed no change of oxLDL [44].
However, we found that both EO and LO reduced
oxLDL compared to FO and OO controls.
Results from previous studies indicate that SDA may
have novel therapeutic efficacy regarding the develop-
ment of type 2 diabetes mellitus [46] and several obesity
related pathologies [40]. In the present study, overweight
adults with parameters of the metabolic syndrome
responded to EO with a lower diastolic blood pressure
and a reduction in blood lipids and serum insulin [20],
which may reduce risk for CVD and type 2 diabetes mel-
litus [25, 46]. However, these effects were independent
of age and BMI - healthy, normal-weight participants
also benefitted from daily EO supplementation (e.g.
decreased TG and insulin) [20]. It is widely accepted
that EPA and DHA have beneficial effects on CVD [47].
However, the mechanisms by which ALA may exert
beneficial health effects remain unclear [reviewed in 4].
To date, there is no high quality evidence to support a
beneficial effect of ALA in reducing cardiac and sudden
death [47]. Therefore, SDA-containing EO may be more
cardioprotective than LO, which only provides ALA, due
to greater conversion to EPA.
Limitations of the current project are that EO and LO
treatments were investigated in two separate studies at
different times (despite the same conditions) and the ab-
sence of a younger, overweight subgroup. Furthermore,
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the control groups, planned for FA comparison, were
smaller than the EO and LO groups.
Conclusions
In conclusion, 8 weeks of supplementation with EO pro-
duced significantly greater increases in plasma, RBC,
and PBMC EPA and DPA, as well as a greater reduction
in AA/EPA compared to LO. However, treatment with
neither EO nor LO maintained blood DHA status in the
absence of fish/seafood consumption. Furthermore, re-
ductions in plasma LDL-C and serum insulin were
greater with EO than with LO. Therefore, daily intake of
SDA-containing EO is a better alternative than LO for
increasing EPA and DPA in blood.
The studies were registered at www.clinicaltrials.gov as
NCT01856179 and NCT0131729.
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